Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Tirzepatide Updates

Diana Isaacs

Weightloss in Menopause

Susan Brian

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz